Loading clinical trials...
Loading clinical trials...
PD-1 Antibody Adjuvant Therapy for Patients With MSI-H Advanced Gastric or Gastroesophageal Junction Cancer After Radical Surgery With D2 Dissection: a Phase II Single-center, Three-arm, Randomized Controlled Clinical Trial
Conditions
Interventions
SOX
XELOX
+2 more
Locations
1
China
Dazhi Xu
Shanghai, China
Start Date
August 25, 2022
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
August 26, 2022
NCT04704661
NCT04550494
NCT06898450
NCT05489211
NCT05702229
NCT04674267
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions